| Current Price | $18.61 | Mkt Cap | $734.7M |
|---|---|---|---|
| Open | $18.34 | P/E Ratio | 0.00 |
| Prev. Close | $18.10 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $17.95 - $19.00 | Volume | 148,614 |
| 52-Wk Range | $7.32 - $21.97 | Avg. Daily Vol. | 189,985 |
| Current Price | $18.61 | Mkt Cap | $734.7M |
|---|---|---|---|
| Open | $18.34 | P/E Ratio | 0.00 |
| Prev. Close | $18.10 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $17.95 - $19.00 | Volume | 148,614 |
| 52-Wk Range | $7.32 - $21.97 | Avg. Daily Vol. | 189,985 |
The best Bull and Bear pitches based on recency and number of recommendations.
Cellectis is new to the Nasdaq and CAPS but it's an old friend to zzporte. Portefeuille originally began buying the stock below 5 in February 2014 and our gains on the stock since then are close to $50000. Portefeuille has a talent for spotting… More
There are no pitches that meet the Top Bear criteria. Explain
If this upsets you, start recommending pitches below!
Read the most recent pitches from players about CLLS.
Recs
odocoileus
(55.41)
Submitted: 1/30/2020 11:54:10 PM :
Start Price:
$16.30
NASDAQ:CLLS Score:
+20.62
CAR-T is an amazing idea. Like all amazing ideas, the devil is in the details. While taking someone's cells, bio-engineering them to recognize cancer cells, and putting them back in the body is crazy smart, the expense and the body's reaction to that process are limiting the success of this technology. While allogenic T-cells do not come from the patient's body, they have some advantages. Namely, price, convenience, safety, and speed. Whether they are as effective remains to be seen, but any effectiveness at all may give allogenic T-cells an advantage for first line use. I like both CLLS and ATRA in this arena. While CLLS broke a lot of ground, ATRA eventually surpassed them. Success in either should draw interest and money into this arena and the share price may see tandem benefits.
Recs
zzlangerhans
(99.44)
Submitted: 3/28/2015 4:23:27 AM :
Start Price:
$36.00
NASDAQ:CLLS Score:
-95.36
Cellectis is new to the Nasdaq and CAPS but it's an old friend to zzporte. Portefeuille originally began buying the stock below 5 in February 2014 and our gains on the stock since then are close to $50000. Portefeuille has a talent for spotting European stocks in hot sectors before the rest of the market catches on and bids them up. In the case of Cellectis it's CAR-T. The potential advantage of Cellectis is that they are generating an allogeneic product that could be marketed "off-the-shelf" unlike the autologous therapeis being developed by Juno and Kite in the US. Cellectis hasn't even filed an IND for any of their CAR-T therapeutics so naturally they fall well into the speculative range of the biotech spectrum. Nevertheless, it's the hottest area in biotech right now so expect a lot of buoyancy in the segment until we see the first major setback or trial failure. We've built up quite a cushion of profits trading Cellectis so I imagine we'll continue to try and milk this cow a while longer.
Find the members with the highest scoring picks in CLLS.
Playa14 (< 20) Score: +76.04
The Score Leader is the player with the highest score across all their picks in CLLS.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| Playa14 | < 20 | 10/17/2019 |
|
5Y | $10.46 | +77.02% | +0.89% | +76.13 | 0 Comment | |
| NextGenStock | 23.94 | 9/11/2019 |
|
5Y | $12.41 | +49.21% | +0.69% | +48.52 | 0 Comment | |
| janaynay | 65.57 | 1/28/2020 |
|
5Y | $16.11 | +14.94% | -7.13% | +22.07 | 0 Comment | |
| odocoileus | 55.41 | 1/27/2020 |
|
5Y | $16.30 | +13.57% | -7.05% | +20.62 | 1 Comment | |
| LukeCrumb | 96.32 | 2/11/2020 |
|
5Y | $17.47 | +5.99% | -10.21% | +16.20 | 0 Comment | |
| DeathStock | 36.50 | 1/28/2019 |
|
5Y | $15.95 | +16.09% | +14.80% | +1.29 | 0 Comment | |
| gunda7907 | < 20 | 1/17/2019 |
|
5Y | $16.90 | +9.60% | +15.40% | -5.80 | 0 Comment | |
| Reallynow222 | 97.51 | 11/19/2018 |
|
5Y | $21.63 | -14.39% | +10.94% | -25.33 | 0 Comment | |
| RossEnd | 96.35 | 8/14/2017 |
|
5Y | $22.57 | -17.96% | +22.41% | -40.37 | 0 Comment | |
| portefeuille3 | 97.80 | 11/8/2017 |
|
5Y | $26.37 | -29.78% | +16.79% | -46.57 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
